Group items tagged

With Healthcare legislation well on its way to ultimate approval and implementation, the winds are now calming and its becoming clearer what the tornado has left behind for the pharmaceutical industry. Many had feared it would result in permanent widespread damage, but it appears the storm may actually have carved a path toward greener pastures for the industry.

CHALLENGE: It's got potential and is ready to be built, but is the science sound? And can a fringe medical treatment have mass appeal?

Lew Lim founder of Mediclights is a MaRS client and is bringing intranasal light therapy to Canada. Peter Adams, a MaRS Life Science and Healthcare IT advisor is working with Lim to commercializing this innovation. They would like to see Toronto as the new hub for interanasal laser research.

Segasist Technologies, a MaRS Discovery District Client, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Prostate Auto-Contouring software 'Segasist P-AC'.

MaRS Innovation and the Samuel Lunenfeld Research Institute of Mount Sinai Hospital are announce that they have entered into an agreement to collaboratively initiate commercialization of an umbilical cord stem cell technology for potential treatment in cardiovascular disease, diabetes and neurological disorders.

According to Theresa Boyle, Health Report of The Star, states that scientists have discovered the process that underlies in the development of cancer cell mutations in breast cancer. Mike Stratton who is part of the International Cancer Genome Consortium at the MaRS Centre states these "findings will go a long way in helping the consortium achieve its goal of mapping the genetic mutations in 50 different types of cancer by 2018."

Robert Lawton Burns focuses on the key role of the 'producers' as the main source of innovation in this wide-ranging analysis of business trends in the manufacturing branch of the health care industry. Written by industry academics and executives, the book provides a detailed overview of the pharmaceutical, biotechnology, genomics/proteomics, medical device and information technology sectors. Most importantly, it describes the growing convergence between these sectors and the need for executives in one sector to increasingly draw upon trends in the others.

"Encycle Therapeutics, a MaRS Innovation spin-off company, has created a ground-breaking chemistry platform for cyclizing peptides that promises to increase the efficiency of the early-stage drug discovery process."